This review discusses the following main toxic effects encountered and anticipated in clinical investigation and practice with antiangiogenic agents in patients with ovarian cancer, with particular focus on potential management strategies:

• Hypertension

• Proteinuria

• Cardiac toxicity

• Vascular thromboembolism

• Haemorrhage

• Gastrointestinal toxicity

• Dermatological toxicity

• Endocrine toxicities